Clinical Trial Update: Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating therapeutic equivalence of CHF5993 pMDI in mild to moderate asthma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF5993 pMDI 100/6/12.5 µg HFA-152a (CHF5993)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 2 | Status: RECRUITING